Arcutis Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
ARQT$27.39+4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands, except share data)
| Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance—December 31, 2020 | 43,338,438 | $4 | $472,569 | $(2) | $(201,950) | $270,621 |
| Issuance of shares of common stock for public offering, net of issuance costs of $603 | 6,325,000 | 1 | 207,489 | — | — | 207,490 |
| Issuance of common stock upon the exercise of stock options | 257,060 | — | 1,265 | — | — | 1,265 |
| Vesting of founder shares subject to repurchase | 37,362 | — | — | — | — | — |
| Lapse of repurchase rights related to common stock issued pursuant to early exercises | 249,239 | — | 176 | — | — | 176 |
| Shares issued pursuant to the ESPP | 48,515 | — | 842 | — | — | 842 |
| Stock-based compensation expense | — | — | 23,892 | — | — | 23,892 |
| Unrealized loss on marketable securities | — | — | — | (253) | — | (253) |
| Net loss | — | — | — | — | (206,356) | (206,356) |
| Balance—December 31, 2021 | 50,255,614 | 5 | 706,233 | (255) | (408,306) | 297,677 |
| Issuance of shares of common stock for public offering, net of issuance costs of $634 | 882,353 | — | 14,366 | — | — | 14,366 |
| Issuance of shares of common stock, net of discount and issuance costs of $10,844 | 8,625,000 | 1 | 161,656 | — | — | 161,657 |
| Issuance of shares of common stock related to the acquisition of Ducentis Biotherapeutics | 610,258 | — | 12,468 | — | — | 12,468 |
| Issuance of common stock upon the exercise of stock options | 331,890 | — | 1,016 | — | — | 1,016 |
| Issuance of common stock upon the vesting of restricted stock units | 118,174 | — | — | — | — | — |
| Lapse of repurchasing rights related to common stock issued pursuant to early exercises | 75,293 | — | 82 | — | — | 82 |
| Shares issued pursuant to the ESPP | 138,821 | — | 1,922 | — | — | 1,922 |
| Stock-based compensation expense | — | — | 32,682 | — | — | 32,682 |
| Unrealized loss on marketable securities | — | — | — | (831) | — | (831) |
| Net loss | — | — | — | — | (311,458) | (311,458) |
| Balance—December 31, 2022 | 61,037,403 | 6 | 930,425 | (1,086) | (719,764) | 209,581 |
| Issuance of common stock and pre-funded warrants, net of issuance costs of $6,546 | 33,425,000 | 3 | 95,762 | — | — | 95,765 |
| Issuance of common stock from ATM offering, net of issuance costs of $116 | 1,250,000 | — | 3,136 | — | — | 3,136 |
| Issuance of common stock upon the exercise of stock options | 348,169 | — | 1,247 | — | — | 1,247 |
| Issuance of common stock upon the vesting of restricted stock units | 440,262 | — | — | — | — | — |
| Lapse of repurchasing rights related to common stock issued pursuant to early exercises | 14,847 | — | — | — | — | — |
| Shares issued pursuant to the ESPP | 271,662 | — | 1,175 | — | — | 1,175 |
| Stock-based compensation expense | — | — | 38,813 | — | — | 38,813 |
| Unrealized loss on marketable securities | — | — | — | 1,186 | — | 1,186 |
| Foreign currency translation adjustment | — | — | — | (96) | — | (96) |
| Net loss | — | — | — | — | (262,140) | (262,140) |
| Balance—December 31, 2023 | 96,787,343 | $9 | $1,070,558 | $4 | $(981,904) | $88,667 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.